Skip to main content
Parnax Lab Limited logo

Parnax Lab Limited — Investor Relations & Filings

Ticker · 506128 ISIN · INE383L01019 BSE.NS Manufacturing
Open in API
Filings indexed 289 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country IN India
Listing BSE.NS 506128

About Parnax Lab Limited

https://naxparlab.com

Parnax Lab Limited specializes in the development and large-scale manufacturing of pharmaceutical formulations, with a primary focus on liquid orals, ointments, creams, and gels. The company operates advanced production facilities compliant with international quality benchmarks, including WHO-GMP standards. It functions as a contract development and manufacturing organization (CDMO), providing end-to-end solutions from formulation development to commercial production for global and domestic healthcare brands. The product range encompasses diverse therapeutic areas such as dermatology, gastrointestinal health, and pediatric care. By integrating modern technology with rigorous quality control processes, the company ensures the delivery of high-stability medicinal products. Its operations are supported by a dedicated research and development wing focused on optimizing delivery systems and enhancing product efficacy for various clinical applications.

Recent filings

Filing Released Lang Actions
Please find enclosed herewith the Intimation regarding the Re-appointment of Mr. Yogesh K. Varia as an Independent Director of the Company, for a second term of 5 consecutive years w.e.f. ....
Regulatory Filings Classification · 75% confidence The document is a formal board meeting outcome notice filed under SEBI LODR Regulations, reporting the approval of audited standalone & consolidated financial results for the quarter and year ended 31 March 2026 and enclosing the auditor’s report, plus a director re-appointment disclosure. It is a regulatory submission to the stock exchange rather than a full annual report, proxy statement, or stand-alone earnings highlights release. It primarily serves as a compliance/regulatory filing under Listing Obligations without being the complete financial report itself. Therefore it falls into the general Regulatory Filings category (RNS).
2026-05-28 English
Please find enclosed herewith the Audited Results for the Quarter and Year Ended March, 2026, along with Auditor''s Report.
Interim / Quarterly Report Classification · 85% confidence The document is the audited standalone & consolidated financial results for the quarter and year ended March 31, 2026, filed under SEBI LODR Regulation 33. It contains full audited financial statements and the auditor’s report, not merely a brief earnings summary or an announcement that a report is available. It is therefore a comprehensive quarterly (and year-end) report, fitting the “Interim / Quarterly Report” (IR) category. FY 2026
2026-05-28 English
Board Meeting Outcome for Consideration and Approval of Standalone & Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March, 2026, along with Auditor's ....
Earnings Release Classification · 85% confidence The document is a formal Board Meeting outcome letter filed with the stock exchange under SEBI LODR Regulations. It announces and submits the Company’s Audited Standalone & Consolidated Financial Results for the quarter and year ended March 31, 2026, along with the Auditor’s Report, and discloses board resolutions (including a director re-appointment). This is the initial public announcement of periodic financial results to shareholders and regulators, matching the definition of an Earnings Release (ER). FY 2026
2026-05-28 English
Parnax Lab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Standalone and Consolidated Audited ....
Regulatory Filings Classification · 88% confidence The document is a notice of a board meeting under Regulation 29 of the Listing Obligation and Disclosure Requirements. It does not announce changes in board composition nor does it contain actual financial results—it simply informs the exchange of the meeting date to approve results. This is a routine regulatory announcement rather than the report itself or a management change. Therefore, it falls under Regulatory Filings (RNS).
2026-05-20 English
Please find enclosed herewith the Compliance Certificate under regulation 74(5) of SEBI (DP) Regulation, 2018.
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued by MUFG Intime India Private Limited under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms the dematerialisation of securities for the quarter ended 31st March 2026, including acceptance/rejection of securities and cancellation of certificates. The document is a regulatory compliance confirmation and does not contain financial statements, management discussion, or any report content. It is short (2151 characters) and serves as a regulatory filing rather than a financial or management report. Therefore, it fits best under Regulatory Filings (RNS).
2026-04-08 English
Financial Results for the Quarter Ended December 31, 2025.
Regulatory Filings
2026-02-13 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.